drugset / Trial / NCT02369068

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

NCT02369068

Completed 21 enrolled Jamie Bartley, DO
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study is to compare the effectiveness of two different medications used in intravaginal trigger point injections (injections into extremely painful areas of a muscle) to treat chronic pelvic pain. The study compares onabotulinumtoxinA (BOTOX®) (a drug prepared from the bacterial toxin botulin which temporarily paralyzes muscles) to Kenalog (a synthetic corticosteroid used as an anti-inflammatory agent).

Timeline

Start
2015-08
Primary completion
2018-03-26
Completion
2018-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 200 iu Other
Comparator Triamcinolone Acetonide Other / unclassified 40 mg Other

Indications